Clinical research organisation Icon has reported revenues of $2.02 billion in the second quarter, up 4.4% year-on-year.
It brings its revenue for the first half of the year to almost $4 billion - or 4.2% higher on the same period of 2022.
The Nasdaq-listed company, which is headquartered in Dublin, reported earnings before interest, tax, depreciation and amortisation of $414.2m - up 16.9% year-on-year.
In the first six months of the year, the firm's earnings stood at $813.4m - up 17% on the same period of 2022.
In its full-year forecasts, Icon said it expects this pace of growth to continue for the rest of the year.
It is guiding revenue of $8.07-8.21 billion for 2023 - which would be 4.3-6.1% higher than 2022.
It also forecast earnings per share of between $12.63 and $12.91. That would be an increase of between 7.5% and 9.9% year-on-year.
We need your consent to load this rte-player contentWe use rte-player to manage extra content that can set cookies on your device and collect data about your activity. Please review their details and accept them to load the content.Manage Preferences
Icon reported net business wins of $2.42 billion for the second quarter - with its backlog of work 2.2% higher at $21.7 billion.
The company employs about 41,160 employees in 108 locations in 53 countries.
"We are encouraged by the positive customer demand trends across our business and have confidence in our long-term growth trajectory," said Icon CEO Dr Steve Cutler.
"Given our strong margin performance, as well as a more favourable tax position, we are revising our adjusted earnings per share range to $12.63 - $12.91, reflecting a year over year increase of 7.5 to 9.9%, an increase of $.04 at the midpoint from our previous guidance range," Dr Cutler said.
